NK Cell therapies
Oncology
Phase 1/2Active
Key Facts
About Celularity
Celularity is a leader in regenerative and cellular medicine, harnessing the unique biology of the postpartum placenta to create a scalable pipeline of allogeneic cell therapies and biomaterial products. With a deep scientific foundation spanning over two decades, the company has transitioned from its origins as Anthrogenesis (founded 1998) to a publicly traded entity with a robust clinical pipeline and commercial capabilities. Its strategy focuses on overcoming traditional barriers in cell therapy—scale, quality, and economics—to deliver effective, off-the-shelf treatments for serious conditions, supported by a seasoned leadership team and integrated manufacturing infrastructure.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Mvasi (bevacizumab biosimilar) | Viatris | Approved |
| DRL-17822 | Dr. Reddy's Laboratories | Phase 2 |
| Biosimilar Portfolio | Zydus Lifesciences | Various |
| therascreen Solid Tumor | Qiagen | Commercial |
| GBR 830 | Glenmark Pharmaceuticals | Phase 1 |
| Bevacizumab Biosimilar | Glenmark Pharmaceuticals | Approved |
| Biosimilar (Bevacizumab) | Ipca Laboratories | Development |
| LockBody Platform Assets | Centessa Pharmaceuticals | Pre-clinical |
| Everolimus | Amneal Pharmaceuticals | Approved |
| Lenalidomide (Revlimid generic) | Amneal Pharmaceuticals | Approved |
| Alymsys (bevacizumab-maly) | Amneal Pharmaceuticals | Approved |
| Pemrydi RTU | Amneal Pharmaceuticals | Approved |